Glenmark Pharmaceuticals has informed that it attached media release today titled ‘Jiangsu Alphamab Biopharmaceuticals, 3D Medicines (Beijing) and Glenmark announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World’.
The above information is a part of company’s filings submitted to BSE.